Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin

Global Methylation Profiling for Risk Prediction of Prostate Cancer

(2012) S. Mahapatra et al.   CLINICAL CANCER RESEARCH

The emerging role of histone lysine demethylases in prostate cancer

(2012) Francesco Crea et al.   Molecular Cancer

Cyclopentenone Prostaglandins with Dienone Structure Promote Cross-Linking of the Chemoresistance-Inducing Enzyme Glutathione Transferase P1-1

(2010) F. J. Sanchez-Gomez et al.   MOLECULAR PHARMACOLOGY

Mechanistic Insights on the Inhibition of C5 DNA Methyltransferases by Zebularine

(2010) Christine Champion et al.   PLoS One

An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer

(2010) J. B. Andersen et al.   Science Translational Medicine

Role of Glutathione Transferases in the Mechanism of Brostallicin Activation

(2009) Silvia Pezzola et al.   BIOCHEMISTRY

Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells

(2009) Madhavi Billam et al.   BREAST CANCER RESEARCH AND TREATMENT

DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine

(2009) Jarah A. Meador et al.   CARCINOGENESIS

Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity

(2009) Domenica Lorusso et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS